Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes: A Randomized Trial
The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Iron chelation therapy (ICT) in patients with lower-risk myelodysplastic syndromes (MDS) has not been evaluated in randomized studies. Objective: To evaluate event-free survival (EFS) and safety of ICT in iron-overloaded patients with low- or intermediate-1-risk MDS. Design: Multicenter, randomized, double-blind, placebo-controlled trial (TELESTO). (ClinicalTrials.gov: NCT00940602). Setting: 60 centers in 16 countries. Participants: 225 patients with serum ferritin levels greater than 2247 pmol/L; prior receipt of 15 to 75 packed red blood cell units; and no severe cardiac, liver, or renal abnormalities. Intervention: Deferasirox dispersible tablets (10 to 40 mg/kg per day) (n = 149) or matching placebo (n = 76). Measurements: The primary end point was EFS, defined as time from date of randomization to first documented nonfatal event (related to cardiac or liver dysfunction and transformation to acute myeloid leukemia) or death, whichever occurred first. Results: Median time on treatment was 1.6 years (interquartile range [IQR], 0.5 to 3.1 years) in the deferasirox group and 1.0 year (IQR, 0.6 to 2.0 years) in the placebo group. Median EFS was prolonged by approximately 1 year with deferasirox versus placebo (3.9 years [95% CI, 3.2 to 4.3 years] vs. 3.0 years [CI, 2.2 to 3.7 years], respectively; hazard ratio, 0.64 [CI, 0.42 to 0.96]). Adverse events occurred in 97.3% of deferasirox recipients and 90.8% of placebo recipients. Exposure-adjusted incidence rates of adverse events (≥15 events per 100 patient treatment-years) in deferasirox versus placebo recipients, respectively, were 24.7 versus 23.9 for diarrhea, 21.8 versus 18.7 for pyrexia, 16.7 versus 22.7 for upper respiratory tract infection, and 15.9 versus 0.9 for increased serum creatinine concentration. Limitations: The protocol was amended from a phase 3 to a phase 2 study, with a reduced target sample size from 630 to 210 participants. There was differential follow-up between treatment groups. Conclusion: The findings support ICT in iron-overloaded patients with low- to intermediate-1-risk MDS, with longer EFS compared with placebo and a clinically manageable safety profile. Therefore, ICT may be considered in these patients. Primary Funding Source: Novartis Pharma AG.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, a randomized study and meta‐analysis clarified that patients who were assigned to an ICT group showed longer survival, with low risk of progression to leukemia, compared with a non‐ICT group.42, 43”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [42]
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationCheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Malcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 865
Tefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 670
Clinical Consequences of Acquired Transfusional Iron Overload in Adults
Schafer, A. I., Cheron, R. G., Dluhy, R., Cooper, B., Gleason, R. E., Soeldner, J. S., & Bunn, H. F. (1981) · New England Journal of Medicine · doi:10.1056/nejm198102053040603 · Cited by 295
Goldberg, S. L., Chen, E., Corral, M., Guo, A., Mody-Patel, N., Pecora, A. L., & Laouri, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2395 · Cited by 289
Malcovati, L., Della Porta, M. G., Strupp, C., Ambaglio, I., Kuendgen, A., Nachtkamp, K., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.044602 · Cited by 282
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Montalban‐Bravo, G., & Garcia‐Manero, G. (2018) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 211
Self-citationRose, C., Brechignac, S., Vassilief, D., Pascal, L., Stamatoullas, A., Guerci, A., Larbaa, D., Dreyfus, F., Beyne-Rauzy, O., Chaury, M. P., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2009.12.004 · Cited by 195
Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.009 · Cited by 173
Research works printed but not linked: 1
- Germing U, 2004, Haematologica, 89, 905
Cited by
Reactive Oxygen Species in Cancer: Current Findings and Future Directions
Nakamura, H., & Takada, K. (2021) · Cancer Science · doi:10.1111/cas.15068 · Cited by 1,027
Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 491
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 216
Self-citationMyelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Montalban‐Bravo, G. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 187
Self-citationFenaux, P., Haase, D., Santini, V., Sanz, G. F., Platzbecker, U., & Mey, U. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.002 · Cited by 163
Hyperferritinemia—A Clinical Overview
Sandnes, M., Ulvik, R. J., Vorland, M., & Reikvam, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092008 · Cited by 158
Myelodysplastic syndromes: moving towards personalized management
Hellström‐Lindberg, E., Tobiasson, M., & Greenberg, P. L. (2020) · Haematologica · doi:10.3324/haematol.2020.248955 · Cited by 117
Self-citationLi, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 100
Weber, S., Parmon, A., Kurrle, N., Schnütgen, F., & Serve, H. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.627662 · Cited by 94
Bruzzese, A., Martino, E. A., Mendicino, F., Lucia, E., Olivito, V., Bova, C., Filippelli, G., Capodanno, I., Neri, A., Morabito, F., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13935 · Cited by 93
Development of luspatercept to treat ineffective erythropoiesis
Kubasch, A. S., Fenaux, P., & Platzbecker, U. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002177 · Cited by 85
Toward a pathophysiology inspired treatment of VEXAS syndrome
Heiblig, M., Patel, B. A., Groarke, E. M., Bourbon, E., & Sujobert, P. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.09.001 · Cited by 76
Current and emerging strategies for management of myelodysplastic syndromes
Saygin, C., & Carraway, H. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100791 · Cited by 70
Clinical decision-making and treatment of myelodysplastic syndromes
Hellström‐Lindberg, E., & Kröger, N. M. (2023) · Blood · doi:10.1182/blood.2023020079 · Cited by 67
Patnaik, M. M., & Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26090 · Cited by 62
Carraway, H. E., & Saygin, C. (2020) · Hematology · doi:10.1182/hematology.2020000127 · Cited by 61
Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae
Kim, C. H., & Leitch, H. A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103367 · Cited by 56
Normal and dysregulated crosstalk between iron metabolism and erythropoiesis
Ginzburg, Y. Z., An, X., Rivella, S., & Goldfarb, A. N. (2023) · eLife · doi:10.7554/elife.90189 · Cited by 51
New Approaches to Myelodysplastic Syndrome Treatment
Bazinet, A., & Bravo, G. M. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00965-1 · Cited by 48
Outpatient transfusions for myelodysplastic syndromes
Wood, E. M., & McQuilten, Z. (2020) · Hematology · doi:10.1182/hematology.2020000103 · Cited by 45
Management of patients with lower-risk myelodysplastic syndromes
Brunner, A. M., Leitch, H. A., van de Loosdrecht, A. A., & Bonadies, N. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00765-8 · Cited by 43
Bewersdorf, J. P., & Zeidan, A. M. (2021) · Cancers · doi:10.3390/cancers13071610 · Cited by 41
Larrue, C., Mouche, S., Angelino, P., Sajot, M., Birsen, R., Kosmider, O., McKee, T., Vergez, F., Récher, C., Mas, V. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1731 · Cited by 37
Lucijanić, M., Lovrinov, M., & Skelin, M. (2020) · Annals of Internal Medicine · doi:10.7326/l20-1055 · Cited by 37
SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade
Volpe, V. O., Garcia‐Manero, G., & Komrokji, R. S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.031 · Cited by 36
Self-citationUnderstanding the Potential and Risk of Bacterial Siderophores in Cancer
Pita-Grisanti, V., Chasser, K. M., Sobol, T., & Cruz‐Monserrate, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.867271 · Cited by 35
Role of reactive oxygen species in myelodysplastic syndromes
Jing, Q., Zhou, C., Zhang, J., Zhang, P., Wu, Y., Zhou, J., Tong, X., Li, Y., Du, J., & Wang, Y. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00570-0 · Cited by 35
Causes and Pathophysiology of Acquired Sideroblastic Anemia
Rodríguez‐Sevilla, J. J., Calvo, X., & Arenillas, L. (2022) · Genes · doi:10.3390/genes13091562 · Cited by 32
Therapeutic potential of induced iron depletion using iron chelators in Covid-19
Naseef, P. P., Elayadeth‐Meethal, M., Salim, K. T. M., Anjana, A., Muhas, C., Vajid, K. A., & Kuruniyan, M. S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.11.061 · Cited by 29
Olíva, E. N., Platzbecker, U., Garcia‐Manero, G., Mufti, G. J., Santini, V., Sekeres, M. A., Komrokji, R. S., Shetty, J. K., Tang, D. H., Guo, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010027 · Cited by 29
Self-citationde Witte, T., Malcovati, L., Fenaux, P., Bowen, D., Symeonidis, A. S., Mittelman, M., Stauder, R., Sanz, G. F., Čermák, J., Langemeijer, S. M. C., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.266817 · Cited by 28
Pilo, F., Cilloni, D., Porta, M. G. D., Forni, G. L., Piperno, A., Santini, V., & Angelucci, E. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106792 · Cited by 28
Self-citationAllogeneic stem cell transplantation for patients with myelodysplastic syndromes
Vittayawacharin, P., Kongtim, P., & Ciurea, S. O. (2022) · American Journal of Hematology · doi:10.1002/ajh.26763 · Cited by 27
Myelodysplastic syndromes: new methods of diagnosis, prognostication, and treatment
Nachtkamp, K., Kobbe, G., Gattermann, N., & Germing, U. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0005 · Cited by 26
Myelodysplastic Syndromes and Metabolism
Balaian, E., Wobus, M., Bornhäuser, M., Chavakis, T., & Sockel, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011250 · Cited by 24
Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
Zhang, X., Yang, X., Ma, L., Zhang, Y., & Wei, J. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231183330 · Cited by 23
Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
Karel, D., Valburg, C., Woddor, N., Nava, V. E., & Aggarwal, A. (2024) · Current Oncology · doi:10.3390/curroncol31040148 · Cited by 21
From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
Palumbo, G. A., Galimberti, S., Barcellini, W., Cilloni, D., Renzo, N. D., Elli, E. M., Finelli, C., Maurillo, L., Ricco, A., Musto, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.752192 · Cited by 21
Loke, J. C. T., Kim, P. G., Nguyen, T. T. P., Boileau, M., McConkey, M. E., Miller, A., Shin, W., Hergott, C. A., Ericsson, M., Nordstrom, A. E. H., et al. (2025) · Blood · doi:10.1182/blood.2024028033 · Cited by 20
Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
Palacios‐Berraquero, M. L., & Piérola, A. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102107 · Cited by 20
Lewis, R., Bewersdorf, J. P., & Zeidan, A. M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s240600 · Cited by 19
An, W., Feola, M., Aluri, S., Ruíz-Martínez, M., Shridharan, A., Levy, M., Fibach, E., Zhu, X., Verma, A., & Ginzburg, Y. Z. (2023) · eLife · doi:10.7554/elife.83103 · Cited by 19
How I treat iron overload in adult MDS
Leitch, H. A., & Buckstein, R. J. (2024) · Blood · doi:10.1182/blood.2023022501 · Cited by 18
Santini, V., Giagounidis, A. A. N., Pelligra, C. G., Franco‐Villalobos, C., Tang, D. H., Morison, J., Beach, C. L., Hu, A., Platzbecker, U., & Fenaux, P. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.05.001 · Cited by 16
Teichman, J., Geddes, M. N., Zhu, N. Y., Keating, M., Sabloff, M., Christou, G., Leber, B. F., Khalaf, D., St‐Hilaire, È., Finn, N., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280723 · Cited by 16
Jouzier, C., Cherait, A., Cony‐Makhoul, P., Hamel, J., Véloso, M., Thépot, S., Cluzeau, T., Stamatoullas, A., Garnier, A., Guerci‐Bresler, A., et al. (2022) · Transfusion · doi:10.1111/trf.16884 · Cited by 15
Bayesian Nonparametric Analysis of Restricted Mean Survival Time
Zhang, C., & Yin, G. (2022) · Biometrics · doi:10.1111/biom.13622 · Cited by 14
Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms
Niscola, P., Gianfelici, V., Giovannini, M., Piccioni, D., Mazzone, C., & de Fabritiis, P. (2024) · Cancers · doi:10.3390/cancers16081563 · Cited by 13
Duarte, T. L., Lopes, M., Oliveira, M., Santos, A. G., Vasco, C. D., Reis, J. P., Antunes, A. R., Gonçalves, A., Chacim, S. P., Oliveira, C., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02067-9 · Cited by 12
Iron chelators as mitophagy agents: Potential and limitations
Brogyányi, T., Kejík, Z., Veselá, K., Dytrych, P., Hoskovec, D., Masařík, M., Babula, P., Kaplánek, R., Přibyl, T., Zelenka, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117407 · Cited by 12
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome
Battaglia, M. R., Cannova, J., Madero‐Marroquin, R., & Patel, A. A. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01217-0 · Cited by 12
Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
Meunier, M., & Park, S. (2022) · eJHaem · doi:10.1002/jha2.523 · Cited by 12
Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
Cassanello, G., Pasquale, R., Barcellini, W., & Fattizzo, B. (2022) · Cancers · doi:10.3390/cancers14194941 · Cited by 11
Rozema, J., van Roon, E. N., Kibbelaar, R. E., Veeger, N. J. G. M., Slim, C. L., de Wit, H., & Hoogendoorn, M. (2021) · Transfusion · doi:10.1111/trf.16631 · Cited by 11
Advances in myelodysplastic syndrome
Santini, V. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000790 · Cited by 10
Parisi, S., & Finelli, C. (2021) · Journal of Blood Medicine · doi:10.2147/jbm.s287876 · Cited by 10
Yang, S. S., Zhang, M. C., Leong, R., Mbuagbaw, L. C. E., Crowther, M. A., & Li, A. (2021) · British Journal of Haematology · doi:10.1111/bjh.17998 · Cited by 10
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Volpe, V. O., & Komrokji, R. S. (2021) · Therapeutic Advances in Hematology · doi:10.1177/2040620720986641 · Cited by 8
Li, J., & Zhang, W. (2022) · Hematology · doi:10.1080/16078454.2022.2132362 · Cited by 10
Self-citationSarocchi, M., Li, J., Li, X., Wu, D., Figueroa, E. H. M., Rodriguez, M. G., Hou, M., Finelli, C., Shi, H., Xiao, Z., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19316 · Cited by 8
Self-citationRobin, M., & Fenaux, P. (2020) · Leukemia · doi:10.1038/s41375-020-0967-x · Cited by 8
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
Lucero, J. A., Al-Harbi, S., & Yee, K. W. L. (2023) · Current Oncology · doi:10.3390/curroncol30070459 · Cited by 7
Gattermann, N. (2024) · Hematology · doi:10.1182/hematology.2024000569 · Cited by 7
Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia
Cappellini, M. D., Taher, A. T., Verma, A. K., Shah, F., & Hermine, O. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101039 · Cited by 7
Merkel, D. G., Soffer, S., Filanovsky, K., Braester, A., Fibach, E., Dana, M., Ofran, Y., Greenbaum, U., Nagler, A., Amitai, I., et al. (2023) · Acta Haematologica · doi:10.1159/000535749 · Cited by 6
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
Gurnari, C., Xie, Z., & Zeidan, A. M. (2022) · Clinical Hematology International · doi:10.1007/s44228-022-00024-4 · Cited by 6
Beyond HMAs: Novel Targets and Therapeutic Approaches
Getz, T. M., Bewersdorf, J. P., Kewan, T. Z., Stempel, J. M., Bidikian, A., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.08.001 · Cited by 6
Supportive Care for Patients With Myelodysplastic Syndromes
Stempel, J. M., Podoltsev, N. A., & Dosani, T. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000661 · Cited by 6
Diagnostic et traitement d’une surcharge en fer
Ruivard, M., & Lobbes, H. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.07.002 · Cited by 6
The Management of Low-Risk Myelodysplastic Syndromes—Current Standards and Recent Advances
Randall, M. P., & Dezern, A. E. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000655 · Cited by 5
Current challenges in conditioning regimens for MDS transplantation
Notarantonio, A., Robin, M., & D’Aveni, M. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101223 · Cited by 5
Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine
Barone, P. D., & Patel, S. S. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.04.008 · Cited by 5
Schulz, F. I., Hauch, U., Ketzler-Henkel, S., von der Heyde, E., Koenigsmann, M., Lauseker, M., Schulte, N., & Germing, U. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206569 · Cited by 5
Rozema, J., van Asten, I., Kwant, B., Kibbelaar, R. E., Veeger, N. J. G. M., de Wit, H., van Roon, E. N., & Hoogendoorn, M. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13865 · Cited by 5
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes
Wang, C., & Sallman, D. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01062-7 · Cited by 5
Nathan, D. I., Feld, J., Jamal, S. M. E., Mascarenhas, J. O., & Tremblay, D. A. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106820 · Cited by 5
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management
Garcia‐Manero, G. (2026) · American Journal of Hematology · doi:10.1002/ajh.70405 · Cited by 4
Self-citationLow‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients
Burke, S., Chowdhury, O., & Rouault‐Pierre, K. (2025) · HemaSphere · doi:10.1002/hem3.70103 · Cited by 4
Hoff, F. W., Schulz, E., Pavletic, S. Z., & Mina, A. A. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101319 · Cited by 4
Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights
Mina, A. A., Madanat, Y. F., Abaza, Y., & Zeidan, A. M. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101301 · Cited by 3
Bauduer, F., & Recanzone, H. (2020) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2020.05.005 · Cited by 3
Gubler, K. D., Offner, K. E., Higham, M. C., & Stephenson, L. G. (2021) · Side effects of drugs annual · doi:10.1016/bs.seda.2021.09.002 · Cited by 3
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes
Volpe, V. O., Garcia‐Manero, G., & Komrokji, R. S. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.001 · Cited by 3
Self-citationTransfusion avoidance in myelodysplastic neoplasms
Griffiths, E. A. (2023) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000794 · Cited by 3
Current Management and New Developments in the Treatment of Myelodysplastic Syndrome
Arslan, S., Khaled, S. K., & Nakamura, R. (2021) · Cancer treatment and research · doi:10.1007/978-3-030-78311-2_7 · Cited by 3
Butler, L. A., Forsyth, C. J., Harrison, C. N., & Perkins, A. C. (2025) · eJHaem · doi:10.1002/jha2.70007 · Cited by 2
Management of iron overload in adult myelodysplastic syndrome
Leitch, H. A., & Buckstein, R. J. (2025) · Hematology · doi:10.1182/hematology.2025000691 · Cited by 2
Kewan, T. Z., Stahl, M., Bewersdorf, J. P., & Zeidan, A. M. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00733-y · Cited by 2
Iron Overload, Oxidative Stress, and Somatic Mutations in MDS : What Is the Association?
Leitch, H. A. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14385 · Cited by 2
Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome
Thomas, X. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2471518 · Cited by 2
Fuchs, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00046-9 · Cited by 2
Iron accelerates MDS progression
Leitch, H. A. (2025) · Blood · doi:10.1182/blood.2024026935 · Cited by 2
Finelli, C., Parisi, S., & Paolini, S. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2077721 · Cited by 2
Levy, M., & Ginzburg, Y. Z. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-92033-2_11 · Cited by 1
Welsch, J., Schulz, F. I., Kasprzak, A., Aul, C., Götze, K. S. S., Nusch, A., Lipke, J., Parmentier, S. B., Strupp, C., Nachtkamp, K., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06736-4 · Cited by 1
Pepe, A., Rizzo, M., Galimberti, S., Baratè, C., Olíva, E. N., Arcioni, F., Storti, S., Renne, S., Midiri, M., Restaino, G., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04495-y · Cited by 1
Treatment of Lower Risk Myelodysplastic Syndromes
Santini, V. (2022) · Hemato · doi:10.3390/hemato3010013 · Cited by 1
Transfusion dependence is a risk factor for severe infections in myelodysplastic syndromes
Pianelli, M., Morsia, E., Lame, D., Carturan, A., Olivieri, A., & Poloni, A. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.107000 · Cited by 1
Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1
Fitzgibbon, J., Park, S., Cook, G., Paiva, B., Gloghini, A., van Breda, E., Busti, F., Garderet, L., Dolcetti, R., Robin, M., et al. (2020) · Hemato · doi:10.3390/bloods1010005 · Cited by 1
Postępowanie terapeutyczne w zespołach mielodysplastycznych niższego ryzyka
Wiśniewski, K., Gołoś, A., & Góra‐Tybor, J. (2021) · Hematologia · doi:10.5603/hem.2020.0042
Metadata
- Authors
- Angelucci, E., Li, J., Greenberg, P., Wu, D., Hou, M., Montaňo Figueroa, E. H., Rodriguez, M. G., Dong, X., Ghosh, J., Izquierdo, M., Garcia-Manero, G., & on behalf of the TELESTO Study Investigators*
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Shanghai Jiao Tong University (CN)
- Stanford Medicine (US)
- First Affiliated Hospital of Soochow University (CN)
- Shandong University (CN)
- Department of Hematology, Hospital General de México, Mexico City, Mexico (E.H.M.)
- Mexican Social Security Institute (MX)
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (X.D., J.G.)
- Novartis (Switzerland) (CH)
- MD Anderson Cancer Center, University of Texas, Houston, Texas (G.G.)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-04-21
- Volume
- 172
- Issue
- 8
- Pages
- 513-522
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3012730855
- Cited by
- 120
- References
- 38
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 24 · 2020: 12
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- iron chelation therapy, deferasirox, myelodysplastic syndrome, iron overload, transfusion dependence, event-free survival, adverse events, cardiac dysfunction, liver dysfunction, acute myeloid leukemia transformation, serum ferritin, red blood cell transfusion, fever
- MeSH terms
- Deferasirox, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Blood Transfusion, Cause of Death, Double-Blind Method, Female, Ferritins, Humans, Iron Chelating Agents, Male, Middle Aged, Myelodysplastic Syndromes, Iron Overload, Young Adult, Patient Acuity, Transfusion Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.